All In Biotech

Drug Trial Radar · NCT05254171

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Aug 8, 2022

Primary completion

Aug 29, 2026

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Panbela Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

Conditions

  • Pancreatic Cancer Metastatic
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer Stage IV

Interventions

  • SBP-101Drug

    small molecule polyamine metabolic inhibitor for subcutaneous injection

  • Nab-paclitaxelDrug

    paclitaxel protein-bound particles for injectable suspension

  • GemcitabineDrug

    gemcitabine for injection

  • PlaceboOther

    Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of first dose up to 100 weeks or until death

Locations

93 sites in 10 countries. Site status is shown where the registry gives one.

  • Genesis Cancer and Blood Institute (SCRI)

    Hot Springs, Arkansas · Withdrawn

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Active not recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • CentraCare Health

    Saint Cloud, Minnesota · Withdrawn

  • Columbia University Medical Center

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Mark H Zangmeister Center - SCRI - PPDS

    Columbus, Ohio · Terminated

  • Tennessee Oncology NASH - SCRI - PPDS

    Nashville, Tennessee · Active not recruiting

  • HOPE Cancer Center of East Texas

    Tyler, Texas · Recruiting

  • Medical Oncology Associates - Spokane

    Spokane, Washington · Recruiting

  • MultiCare Regional Cancer Center - Tacoma

    Tacoma, Washington · Recruiting

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Canberra Region Cancer Centre

    Garran, Australia Capital Territory, Australia · Recruiting

  • The Tweed Hospital

    Tweed Heads, New South Wales, Australia · Withdrawn

  • Ashford Cancer Centre Research

    Kurralta Park, South Australia, Australia · Recruiting

  • Austin Hospital

    Heidelberg, Victoria, Australia · Recruiting

  • St John of God Murdoch Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Kepler Universitätsklinikum Linz

    Linz, Austria · Recruiting

  • Salzburg Cancer Research Institute

    Salzburg, Austria · Active not recruiting

  • A.ö. Krankenhaus der Barmherzigen Brüder

    Wein, Austria · Recruiting

  • Landesklinikum Wiener Neustadt

    Wiener Neustadt, Austria · Recruiting

  • Klinikum Klagenfurt Am Woerthersee

    Klagenfurt, Carinthia, Austria · Recruiting

  • Universitätsklinikum St. Pölten

    Sankt Pölten, Lower Austria, Austria · Recruiting

  • Ordensklinikum Linz, Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H

    Linz, Upper Austria, Austria · Not yet recruiting

  • Pyhrn-Eisenwurzen Klinikum Steyr

    Steyr, Upper Austria, Austria · Withdrawn

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Upper Austria, Austria · Recruiting

  • Landeskrankenhaus Feldkirch

    Rankweil, Vorarlberg, Austria · Recruiting

  • Grand Hopital de Charleroi asbl

    Charleroi, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • CHU de Liège

    Liège, Belgium · Recruiting

  • Imelda VZW

    Bonheiden, Antwerpen, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgique, Belgium · Not yet recruiting

  • Hôpital de Jolimont

    La Louvière, Hainaut, Belgium · Recruiting

  • Centre Hospitalier de l'Ardenne

    Libramont, Luxembourg, Belgium · Recruiting

  • CHU UCL Namur asbl - Site Godinne

    Yvoir, Namur, Belgium · Recruiting

  • Onze-Lieve-Vrouwziekenhuis

    Aalst, Oost-Vlaanderen, Belgium · Recruiting

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • AZ Groeninge

    Kortrijk, West-Vlaanderen, Belgium · Recruiting

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.